1. FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC (targetedonc.com)
2. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial - The Lancet Respiratory Medicine